CMS has advised Scope Fluidics on an agreement with Bio-Rad Laboratories under which it received USD 30 million in settlement of conditional payments related to the sale of the Curiosity Diagnostics SPV.
Schoenherr Advises InPharm Co on Acquisition of Casa Spadijer Bioclinica
Moravcevic Vojnovic and Partners in cooperation with Schoenherr has advised InPharm Co on its acquisition of Casa Spadijer Bioclinica.
TGS Baltic Advises InMedica Group on Acquisition of Druskininkai Pusynas Rehabilitation Clinic
TGS Baltic has advised InMedica Group on its acquisition of Druskininkai Pusynas Rehabilitation Clinic in Lithuania from Vytautas Dambrava.
White & Case and GKC Partners Advise Ronesans Holding on EUR 456 Million PPP Healthcare Project in Kazakhstan
White & Case and its Turkish affiliate GKC Partners have advised Ronesans Holding's subsidiary Renell Kokshetau on the financing of a EUR 456 million public-private partnership healthcare project for the construction and operation of a hospital in Kazakhstan. Clifford Chance reportedly advised the financing institutions.
Papapolitis & Papapolitis, KLC, and Zepos & Yannopoulos Advise on Armira and Viessmann's Minority Stake Acquisition in Pharos Generics
Papapolitis & Papapolitis, working with White & Case, has advised Germany-based investment holding Armira and Viessmann Generations Group on the acquisition of a minority stake in Pharos Generics Holding from Diorama Investments, Limonilum, Amarilenco, and Hesperiada. KLC advised Pharos Generics Holding as well as Limonilum, Amarilenco, and Hesperiada. Zepos & Yannopoulos advised Diorama Investments. Latham & Watkins was reportedly the sellers' international counsel.
A&O Shearman Advises BHM Group on Entering the UK Market
A&O Shearman has advised Reinsberg Group on its acquisition of a majority stake in Brandon Medical. Veronique Marot & Co Solicitors reportedly advised Brandon Medical.
Life Sciences Bulletin: Parallel Import of Medicines into Ukraine as of 2025
Starting on 1 January 2025, the parallel import of medicines into Ukraine will come into force, allowing dealers that are authorised by manufacturers of medicinal products to import medicines in parallel with said manufacturers. The expected outcomes of this new regime are higher competition and lower prices for relevant medicines.